Late-stage biotechnology company Rocket Pharmaceuticals, Inc. (RCKT), Tuesday announced the appointment of Aaron Ondrey, as Chief Financial Officer.
Aaron Ondrey has over 20 years of experience in financial management, strategic planning, commercial finance, capital allocation and mergers and acquisitions.
Ondrey most recently served as CFO of Mirati Therapeutics through the launch of Krazati and the company's acquisition by Bristol Myers Squibb in January 2024.
"Today's leadership announcements underscore Rocket's preparedness as we transform from a clinical organization to a commercial stage gene therapy company, notably by expanding our financial expertise with the addition of seasoned finance leader, Aaron Ondrey as our Chief Financial Officer," said Gaurav Shah, Chief Executive Officer, Rocket Pharma. "We are leveraging our team's deep talent and experience to optimally position Rocket for operational and commercial excellence and look forward to continuing our strong momentum as we advance our leading pipeline for patients living with rare cardiovascular and hematologic diseases."
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.